U.S.A. approves of post-born depression pill

The US Food and Bars Administration said the jarlon, sold under the name of the Zurzuvae brand, has been adopted as a pill once a day taken for two weeks.

So far, treatment for post-born depression was only available as an intravenous injection, the FDA said, the BBC reported.

Drug producers Sage Therapeutics and Biogen said the pill is expected to be available later this year. Its price has not yet been announced, Klen Kosova.tv broadcasts.

Like other forms of depression, post - birth depression symptoms may include sadness, energy loss, suicidal thinking, lowering the ability to feel satisfaction, or cognitive injury.

“Depression after birth is a serious and potentially life threatening state in which women experience sadness, guilt, inadequacy even, in serious cases, thoughts to hurt themselves or their child”, said Tiffany Farchione, leader of psychiatry at the FDA Drug Centre.

And because post-born depression can disrupt the mother-child bond, there may also be consequences for the child's physical and emotional development.

Access to an oral treatment will be useful for many women who face extreme and sometimes life threatening”, she added.

Clinical trials showed that the pills helped reduce the significant symptoms of depression within three days. The drug effect was held four weeks after the last dose, the FDA said.

The agency said the label contains a warning in the box, noting that Zurzuvae could influence a person's ability to drive and perform other potentially dangerous activities. He recommends that patients avoid running or using heavy machinery for at least 12 hours after receiving it.